Pragmatic Strategies to Help Pregnant Smokers Quit

By Peter Selby MBBS, CCFP, and Rosa Dragonetti, MSc.

Maternal smoking is the leading cause of poor pregnancy outcomes, including neonatal morbidity and mortality. However, the behavioural effects on the baby often manifest later in life. The damage begins with DNA adducts in paternal sperm due to the incorporation of tobacco smoke into the zygote. The damage continues if the mother smokes while pregnant. The nicotine, cadmium, thiocyanates, and carbon monoxide present in smoke mediate the harm. Although the true prevalence of smoking in pregnancy is unknown, at least 11% of Canadian women admit to smoking during their most recent pregnancy. While pregnancy is a time of change, most pregnant smokers do not quit. Of those who do, most stop during the first trimester and, at best, 30% will respond to a behavioural intervention. The use of pharmacotherapy is controversial, but should be added if behavioural interventions are not working by themselves. Breastfeeding is recommended even if a woman continues to smoke or uses nicotine replacement therapy (NRT). However, although bupropion may be used during pregnancy, it should not be used while breastfeeding. There is insufficient evidence on the safety of varenicline during pregnancy and, therefore, it should be avoided at this time. The role of healthcare providers in treating pregnant patients who smoke is crucial and they should prescribe pharmacotherapy when necessary to help them stop for good.

Cigarettes contain approximately 4000 chemicals, including 50 to 60 known carcinogens. Between one-third to one-half of smokers will die from smoking-related diseases, and 50% of these deaths will be premature deaths. The use of tobacco products in women of child-bearing age is a particular concern, not only because of the effects on their own health, but also on their reproductive health. Although many healthcare providers focus on the effects of smoking while a woman is pregnant, it is important to note that there is a dose-response relationship between the number of cigarettes smoked and effects on the developing fetus. Therefore, eliminating exposure, even before a woman becomes pregnant, is ideal. Since most pregnancies are unplanned, however, many female smokers find themselves pregnant and then attempt to stop.

According to the Canadian Tobacco Use Monitoring Survey (CTUMS), the prevalence of smoking in women aged 20 to 44 is 9.8%. In 2003, women aged 20 to 44 years were asked about smoking during any pregnancy during the previous 5 years. Approximately 11% admitted to smoking and at least 12% stated that their spouses smoked regularly at home when they were pregnant. These figures certainly underestimate the true prevalence of smoking due to the demand characteristics of survey questions. In the United States, smoking costs $250 million in direct medical costs each year. The largest smoking-attributable costs are due to low birth-weight and lower respiratory tract infections. The additional costs during the first year after birth range from $1142 to $1358 per smoking pregnant woman. An annual percentage point decrease in smoking prevalence among pregnant women could prevent the delivery of 1300 low birth-weight infants, thereby, saving about $21 million in direct medical costs during the first year alone.

Natural history of smoking in pregnancy

It is estimated that between 25% and 40% of women who become pregnant will try to stop smoking once they learn that they are pregnant. One study in Nova Scotia revealed...
Tobacco smoke is toxic. Only 8.5% of women who were smokers at their first prenatal visit were nonsmokers at the time of delivery, while 13.1% maintained their smoke-free status throughout their pregnancy. Furthermore, 20% of those who had quit at the time of their first prenatal visit had relapsed by the time they delivered. For those who continued to smoke, there appeared to be a reduction in the total number of cigarettes smoked daily (by 2 cigarettes) over the course of the pregnancy. However, given the ability of smokers to compensate by smoking intensely to achieve the same level of nicotine, this is not a clinically-significant reduction.

Women who continue to smoke while pregnant generally are younger and single (odds ratio [OR]=4.8, 95% confidence interval [CI], 3.8-6.0), or have a low level of education, a socioeconomic disadvantage, concurrent mental health problems, and/or other addictions, low self-esteem, and/or are living with a partner who smokes (OR 2.3, 95% CI, 1.9-2.7). Nevertheless, 50% of pregnant women report cutting down when planning to become pregnant or once they find out that they are pregnant. An additional 2%-22% may quit later in their pregnancy.

Pregnant women who cut down their smoking and those who quit “cold turkey” experience withdrawal symptoms. The only difference is that smokers have mild withdrawal because of continued smoking, while those who quit report significant irritability and difficulty concentrating. Moreover, relapse in the postpartum period is substantial. Between 50% and 60% of women who quit during their pregnancy relapse to smoking within 6 months postpartum. In a pilot study examining the timing and predictors of postpartum relapse, 50% of women relapsed within days of their delivery. Mothers who had lower levels of education, were poor, living in households where others smoked, and who were not breastfeeding were more likely to relapse. Further, women indicated that the primary reasons for relapse were stress and exposure to others smoking, and who were not breastfeeding were poor, living in households where others smoked, and who were not breastfeeding were more likely to relapse. Further, women indicated that the primary reasons for relapse were stress and exposure to another person smoking.

The effects of tobacco smoke on oocytes: Smokers enter menopause approximately 1 to 4 years earlier than nonsmokers, primarily due to the anti-estrogen effects of tobacco smoke. The damage to a woman’s ovaries from tobacco smoke occurs in those exposed to tobacco smoke as a fetus in utero. Advancing the age of menopause requires the destruction of 25% of oocytes at birth. Moreover, smokers attending infertility treatment have an increased proportion of diploid oocytes, i.e., the percentage of abnormal oocytes in smokers is 20% versus <5% in nonsmokers, while ex-smokers and light smokers have about 12% abnormal oocytes. Therefore, women should quit smoking before they get pregnant.

Effects of tobacco smoke on pregnancy: There have been several reviews on the effects of smoking during pregnancy. Although women who smoke are less likely to experience preeclampsia in pregnancy, the overall effects of smoking are detrimental to both the mother and the fetus. Early pregnancy complications include ectopic pregnancy with a relative risk (RR)=2.2; 95% CI, 1.3-3.6, compared to nonsmokers, and spontaneous abortion with a RR=1.8; 95% CI, 1.3-2.5). Other pregnancy complications include an increased incidence of placenta previa (RR=2.6; 95% CI, 1.3-3.5), prematurity, abruptio placenta, and preterm rupture of membranes.

Effects of tobacco smoke on the fetus and the infant: The immediate effects on the fetus are observable, with inhibition of fetal breathing and, occasionally, fetal movement during, or immediately after, a woman smokes a cigarette. There is also decreased fetal heart rate variability. Moreover, there are detectable withdrawal symptoms in infants born to smoking mothers. Selby reported a case of intrauterine fetal withdrawal when a mother tried to quit cold turkey in the second trimester.

The most important reason for intrauterine growth retardation (IUGR) and subsequent low birth weight in developed nations is maternal smoking. The IUGR tends to be symmetrical and can be observed at 22 weeks gestation, with the relative risk ranging from 2.41 to 4.0, depending on the population studied. Given that most fetal weight gain occurs during the third trimester, smoking during this trimester has the most severe effects on birth weight, resulting in IUGR and infant prematurity. The decrease in birth weight is inversely related to the number of cigarettes smoked and exposed infants may weigh between 150-300 gms less than unexposed infants. Mothers exposed to environmental tobacco smoke or second-hand smoke have infants who weigh about 107 gms less than unexposed infants. Furthermore,
Anxiety

Women who To decrease the Inhaled hydrogen Nicotine inhaled with tobacco cellular oxygen utilization, interfere with vitamin B12 in the liver. At higher doses, cyanide and thiocyanate are cyanide is rapidly absorbed and converted to thiocyanate. Furthermore, nicotine crosses the placenta and leads to increases in fetal blood pressure and heart rate.

However, transdermal nicotine has less effect on catecholamine release than does smoking.57 Studies on the effects of nicotine in pregnant rats reveal that continuous nicotine infusion leads to more neuroteratogenic effects in offspring than pulsed nicotine doses.58 However, the doses used were much higher than those observed in heavy human smokers or in those using NRT.59 Regardless, based on the above findings, Slotkin theorizes that continuous nicotine exposure, as in transdermal NRT, might be more harmful to light smokers and those who have periods of abstinence during the day.58 He recommends the use of NRT in the first trimester, with discontinuation in the second and third trimester due to the absence of nicotinic receptor expression in early pregnancy; however, he acknowledges that heavy smokers who maintain a steady level of plasma nicotine throughout the day are also exposed to other noxious substances in cigarette smoke. Therefore, any effective NRT regimen has to provide a lower dose of nicotine and allow for a nicotine-free period that allows DNA synthesis to occur, thus minimizing the detrimental effects of nicotine on the developing brain. This intervention will also prevent the hypoxic effects associated with smoking and protect the fetus from exposure to carbon monoxide and hydrogen cyanide.

Smoking cessation in pregnant smokers

Comorbid psychiatric conditions and smoking: Anxiety and depressive disorders are very common in smokers.60,61 In addition, negative mood states post-cessation predict early relapse, and the use of alcohol and other drugs of abuse increase the odds that a woman will not stop smoking. Hence, it is important to also screen for these problems in all pregnant smokers.

Interventions with pregnant women: To decrease the prevalence of smoking during pregnancy, both a population and clinical approach should be adopted. Policies and interventions that aim to prevent women and men who are considering having a child from smoking are necessary. In clinical settings, it is important to screen all patients, including pregnant women, for smoking and to intervene aggressively to help them stop, not just during the pregnancy, but also for their entire life. Furthermore, it is recommended to use behavioural and psychosocial interventions that have been adapted for pregnant women in the first trimester. If they are unable to quit or “stay
Pharmacotherapy may be added under the supervision of a trained healthcare provider. It is imperative to address smoking within the family, particularly that of her partner or other members in her household.

**Psychosocial interventions:** Due to the benefits of quitting smoking for both the mother and the fetus, all pregnant smokers should be offered counselling proven to be efficacious in pregnant smokers. Although validated primarily in the United States, the modified Smoking Cessation or Reduction in Pregnancy Treatment (SCRIPT) Model was derived from 2 meta-evaluations and 2 meta-analyses. It includes the use of motivational strategies that incorporate pregnancy-specific counselling strategies, a patient education video, *Commit to Quit Smoking – During and After Pregnancy*, and the use of a validated self-help manual, *Pregnant Woman’s Self-Help Guide to Quit Smoking*. A recent study of 948 pregnant smokers has also demonstrated the efficacy of proactive telephone counselling in pregnant smokers with a self-reported cessation rate of 20%.

The desk reference in Figure 1 provides an outline of the benefits of quitting smoking and the steps to screening and referring pregnant women for cessation counselling.

**Pharmacological interventions:** The safety of NRT in pregnancy is a concern for practitioners; therefore, most avoid recommending its use in smokers. There have been at least 2 negative trials of NRT in pregnancy. In both randomized trials, the NRT patch was applied for approximately 16 hours and removed at night. Wisborg enrolled pregnant smokers (n=250) who smoked >10 cigarettes per day in their second trimester. Women were randomized to NRT or placebo patches for 11 weeks. There were no differences in results between the NRT and placebo group; however, these findings were due to inadequate doses of NRT and high drop-out rates.

Interestingly, pregnant women demonstrate increased nicotine metabolism in the late second and third trimester. In some studies, minimal-effective doses of nicotine in immediate-release formats (eg, gum) are thought to allow for nicotine-free periods. However, if a woman continues to smoke ≥1 cigarette every waking hour, then long-acting preparations such as the NRT patch may be more suitable. Furthermore, breastfeeding while using NRT provides the same level – or less – of nicotine to the infant, without the other chemicals in smoke.

Bupropion is considered less dangerous than NRT during pregnancy, with the advantage of providing antidepressant effects. However, the risk of seizures makes it the second choice for many clinicians treating pregnant smokers. Bupropion is not recommended while a woman is breastfeeding due to the risk of seizures in the infant.

There have been no studies on the safety and efficacy of varenicline in

---

**Figure 1. Benefits of Quitting Smoking**

<table>
<thead>
<tr>
<th>Benefits of quitting for the woman</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Decreased risk of developing cancers, heart disease, stroke, and circulatory problems</td>
</tr>
<tr>
<td>• Decreased risk of respiratory diseases (asthma, emphysema, chronic bronchitis, flu, colds, pneumonia)</td>
</tr>
<tr>
<td>• Decreased risk of developing peptic ulcers, tooth loss, gum disease, osteoporosis, thyroid disease, and menstrual problems</td>
</tr>
</tbody>
</table>

**Benefits of quitting for the pregnancy**

<table>
<thead>
<tr>
<th>Benefits of quitting for the pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Decreased risk of spontaneous abortion and perinatal mortality</td>
</tr>
<tr>
<td>• Decreased risk of vaginal bleeding, premature delivery, developing abruptio placenta and placenta previa</td>
</tr>
<tr>
<td>• Decreased effect on quality and quantity of breast milk</td>
</tr>
</tbody>
</table>

**Benefits of eliminating exposure to second hand smoke exposure by infants and children**

<table>
<thead>
<tr>
<th>Benefits of eliminating exposure to second hand smoke exposure by infants and children</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Decreased risk of Sudden Infant Death Syndrome</td>
</tr>
<tr>
<td>• Decreased risk of children developing asthma and allergies</td>
</tr>
<tr>
<td>• Reduced risk of middle ear infections</td>
</tr>
<tr>
<td>• Less chance of cranky and colicky babies</td>
</tr>
</tbody>
</table>

**“RISK” is defined as the chance of experiencing the negative consequences, but it does not mean that it will definitely occur.**

**ASK**

- How many cigarettes do you smoke?
- How do you feel about quitting smoking?
- Does anyone smoke around you or your children?

**Smokes**

<table>
<thead>
<tr>
<th>Smokes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strongly advise patient to quit. Offer help or refer her to Smokers Helpline or Motherisk even if they are not ready to quit. Ask about exposure to second-hand smoke.</td>
</tr>
</tbody>
</table>

**Does not smoke**

<table>
<thead>
<tr>
<th>Does not smoke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Educate ways to decrease exposure to second hand smoke.</td>
</tr>
<tr>
<td>• Encourage family/friends who smoke to quit</td>
</tr>
<tr>
<td>• Encourage family/friends not to smoke around the pregnant woman, the infant, or child</td>
</tr>
<tr>
<td>• Do not allow smoking in the home or vehicle</td>
</tr>
<tr>
<td>• Do not frequent places that allow smoking</td>
</tr>
</tbody>
</table>

**Smokers Helpline**

1-877-513-5333

www.pregnets.org

Motherisk

1-877-327-4636
pregnant smokers. It should be avoided until more data become available.

**Preventing smoking relapse:** Given the high rate of relapse postpartum, it is strongly recommended that women be counselled and supported in maintaining their smoke-free status ante-partum and immediately postpartum. Strategies to enhance and prolong breastfeeding and frequent follow-up will help delay, if not prevent, relapse to smoking. It is important to discuss the need to stay smoke-free with the patient, not only for her own reproductive health, but also if she is planning another pregnancy in the future. If a decision is being made about the use of oral contraception, then the importance of staying smoke-free should be stressed, since smoking while using oral contraception is associated with its own set of risks.

**Dealing with relapse:** If a woman experiences a relapse at any point during the process, she should be encouraged to report it immediately to her health-care practitioner or counsellor. Counselling and optimization of pharmacotherapy may be necessary to prevent a full-blown return to smoking.

**Conclusion**

Healthcare practitioners have a role in providing education and intervention to couples who are contemplating pregnancy, as well as intervening when a woman is pregnant. A woman-centred approach that addresses the social and other determinants of her smoking will help her and her offspring have the best odds of a healthy outcome and break the cycle of the habit.

For a list of resources on smoking cessation with pregant and post-partum women, visit www.pregnets.org.

**Rosa Dragonetti** is the Manager of the Nicotine Dependence Service at the CAMH that includes projects such as the STOP Study, the TEACH project, and PREGNETS (www.pregnets.org). Rosa also contributed to the development and implementation of CAMH’s Smoke-Free Policy, the Rainbow Tobacco Intervention Project, Tobacco Control Area Network Steering Committee, and the Provincial Cessation Task Group.

**References**


Upcoming Meeting

27 February – 1 March 2008
Society for Research on Nicotine and Tobacco (SRNT) 14th Annual Meeting
Hilton Portland and Executive Tower
Portland, Oregon, USA
Contact: www.srnt.org
10-13 April 2008
American Society of Addiction Medicine (ASAM)
Toronto, Ontario
Contact: www.asam.org

Disclosure Statement: Rosa Dragoneff has stated that she has no disclosures to announce in the contents with the assistance of this issue. Dr. Selby is a paid consultant and advisory board member for Pfizer Consumer Healthcare, Canada; Pfizer Inc, Canada; Sanofi-Synthelabo, Canada; GlaxoSmithKline, Canada; GSK Pharm and Prempharm Inc., Canada; and the Canadian Training Institute (CTI). Grants include: Health Canada; Smoke-Free Ontario (SFO), Ministry of Health Promotion, Government of Ontario; and the Canadian Institutes of Health Research (CIHR). He has received no tobacco industry funds.